ENANTA PHARMACEUTICALS INC ENTA
We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications.
We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie's leading brand of direct-acting antiviral, or DAA, combination treatment for HCV, which has been marketed under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET® was also approved as the first and only treatment for acute HCV infection in June 2025.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M |
| R&D | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M | $136.8M | $142.2M | $94.9M | $57.5M | $40.5M |
| SG&A | $43.9M | $57.9M | $52.9M | $45.5M | $32.5M | $27.4M | $26.2M | $23.4M | $20.7M | $17.0M |
| Total operating expenses | $150.7M | $189.3M | $216.4M | $210.0M | $206.6M | $164.1M | $168.5M | $118.3M | $78.2M | $57.4M |
| Operating income | -$85.3M | -$121.7M | -$137.2M | -$123.8M | -$109.6M | -$41.6M | $36.7M | $88.3M | $24.6M | $30.8M |
| Interest expense | $7.7M | $10.9M | $5.1M | $0 | $0 | — | — | — | $40.0K | $45.0K |
| Pre-tax income | -$83.5M | -$117.8M | -$131.0M | -$122.2M | -$107.6M | -$35.0M | $45.6M | $93.1M | $26.9M | $32.6M |
| Income tax | $1.7M | $1.7M | $2.8M | $433.0K | $28.6M | $1.1M | $826.0K | $21.2M | $9.2M | $10.9M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M | -$79.0M | -$36.2M | $46.4M | $72.0M | $17.7M | $21.7M |
| EPS, basic | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.74 | 0.93 | 1.14 |
| EPS, diluted | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 |
| Shares, diluted (wtd. avg.) | $21.3K | $21.2K | $21.0K | $20.6K | $20.2K | $19.9K | $21.0M | $20.6M | $19.4M | $19.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $32.3M | $37.2M | $85.4M | $44.0M | $57.2M | $87.1M | $51.2M | $63.9M | $65.7M | $16.6M |
| Short-term investments | $156.6M | $211.0M | $284.5M | $205.2M | $186.8M | $299.5M | $284.0M | $244.8M | $158.0M | — |
| Receivables | $6.9M | $6.6M | $8.6M | $20.3M | $23.6M | $23.5M | $51.3M | $67.2M | $10.6M | $12.8M |
| Total current assets | $204.3M | $299.9M | $422.8M | $311.7M | $319.0M | $436.8M | $401.8M | $380.4M | $237.8M | $232.2M |
| Property, plant and equipment | $35.4M | $32.7M | $11.9M | $6.2M | $5.9M | $8.6M | $10.9M | $8.4M | $8.0M | $8.0M |
| Total assets | $280.7M | $376.7M | $462.3M | $375.4M | $438.8M | $486.1M | $489.8M | $414.2M | $326.6M | $281.3M |
| Accounts payable | $1.9M | $8.0M | $4.1M | $6.0M | $9.5M | $5.7M | $6.7M | $4.7M | $3.7M | $3.4M |
| Total current liabilities | $48.6M | $57.5M | $62.8M | $29.8M | $36.2M | $24.2M | $22.6M | $16.0M | $21.0M | $7.9M |
| Total liabilities | $216.0M | $247.8M | $245.5M | $54.1M | $39.4M | $30.6M | $27.3M | $20.5M | $25.0M | $11.3M |
| Retained earnings | -$404.9M | -$323.0M | -$207.0M | -$73.2M | $48.6M | $127.6M | $163.7M | $117.4M | $45.4M | $27.6M |
| Total equity | $64.7M | $128.8M | $216.7M | $321.3M | $399.4M | $455.6M | $462.5M | $393.7M | $301.7M | $269.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.3M | -$78.8M | -$103.2M | -$84.8M | -$70.0M | $7.1M | $71.4M | $29.2M | $52.7M | $35.8M |
| Stock-based compensation | $18.6M | $26.8M | $28.2M | $27.0M | $21.0M | $19.6M | $19.2M | $15.8M | $13.1M | $9.4M |
| Capital expenditure | $12.9M | $17.9M | $9.1M | $2.1M | $750.0K | $1.4M | $5.4M | $3.0M | $2.5M | $4.7M |
| Investing cash flow | $40.3M | $58.2M | -$53.6M | $54.9M | $37.0M | $19.8M | -$86.7M | -$35.4M | -$4.6M | -$43.7M |
| Financing cash flow | -$26.6M | -$27.6M | $198.1M | $20.0M | $3.1M | $9.0M | $2.6M | $4.4M | $1.0M | $2.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-25-288121.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |